IRF9 and myeloid sarcoma: Indeed, IRF7 is a significant regulatory factor in the development of demyelination diseases in the CNS, such as MS and EAE33, whereas IRF9 is important in injury-induced type 1 IRF signaling, which regulates inflammatory responses in the CNS50.